All In Biotech

Drug Trial Radar · NCT03852472

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

A Randomized , Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 435 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

435

Actual

Start

Dec 21, 2018

Primary completion

Jan 14, 2021

Study completion Mar 9, 2021

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Feb 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

Conditions

  • Hidradenitis Suppurativa
  • Acne Inversa

Interventions

  • AvacopanDrug

    Active treatment

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12.Time frame: Baseline to Week 12

Locations

91 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site

    Birmingham, Alabama

  • Clinical Site

    Birmingham, Alabama

  • Clinical Site

    Mobile, Alabama

  • Clinical Site

    Phoenix, Arizona

  • Clinical Site

    Scottsdale, Arizona

  • Clinical Site

    Fort Smith, Arkansas

  • Clinical Site

    Rogers, Arkansas

  • Clinical Site

    Fountain Valley, California

  • Clinical Site

    Fremont, California

  • Clinical Site

    Fullerton, California

  • Clinical Site

    Huntington Beach, California

  • Clinical Site

    Inglewood, California

  • Clinical Site

    Los Angeles, California

  • Clinical Site

    Los Angeles, California

  • Clinical Site

    Los Angeles, California

  • Clinical Site

    Manhattan Beach, California

  • Clinical Site

    Newport Beach, California

  • Clinical Site

    Northridge, California

  • Clinical Site

    Redwood City, California

  • Clinical Site

    Thousand Oaks, California

  • Clinical Site

    Walnut Creek, California

  • Clinical Site

    Boca Raton, Florida

  • Clinical Site

    Clearwater, Florida

  • Clinical Site

    Hialeah, Florida

  • Clinical Site

    Hollywood, Florida

  • Clinical Site

    Homestead, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Ocala, Florida

  • Clinical Site

    Orlando, Florida

  • Clinical Site

    Pembroke Pines, Florida

  • Clinical Site

    Tampa, Florida

  • Clinical Site

    Tampa, Florida

  • Clinical Site

    Tampa, Florida

  • Clinical Site

    Weston, Florida

  • Clinical Site

    Atlanta, Georgia

  • Clinical Site

    Marietta, Georgia

  • Clinical Site

    Newnan, Georgia

  • Clinical Site

    Sandy Springs, Georgia

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.